Cellectis SA
(STU:ZVAA)
€
1.58
0.1 (6.76%)
Market Cap: 158.14 Mil
Enterprise Value: 5.54 Mil
PE Ratio: 0
PB Ratio: 1.45
GF Score: 69/100 Cellectis SA at Goldman Sachs Global Healthcare Conference Transcript
Jun 16, 2022 / 05:00PM GMT
Release Date Price:
€2.26
(-5.04%)
Matthew (Trades, Portfolio)atorre
Goldman Sachs Group, Inc., Research Division - Research Analyst
Good morning, everyone, and thank you for joining us for Day 4 of the Goldman Sachs Healthcare Conference. We're really pleased to have Cellectis here. And with us, we have Bing Wang, CFO. So just to get started. So Cellectis is a clinical-stage biotech company using its platform to develop cell therapies.
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot